RADIATION THERAPY FOLLOWED BY DURVALUMAB (MEDI4736) AND TREMELIMUMAB AND SURGERY VERSUS RADIATION THERAPY FOLLOWED BY SURGERY FOR RESECTABLE HEPATOCELLULAR CARCINOMA. A RANDOMIZED WINDOW OF OPPORTUNITY TRIAL (DARTS)

Registry ID

ESR-23-22174

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

HAMILTON HEALTH SCIENCES CORPORATION

Start date

2025-09-22

Last update

2025-04-07

Conditions

• HEPATOCELLULAR CARCINOMA

Related clinical trials

• A MULTICENTER, OPEN LABEL, NON-RANDOMIZED FIRST-IN-HUMAN PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY,PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF BAY 3547926 ALONE, AND IN COMBINATION, IN PARTICIPANTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
• PERIOPERATIVE THERAPY WITH DURVALUMAB PLUS TREMELIMUMAB FOR PATIENTS WITH RESECTABLE HEPATOCELLULAR CARCINOMA (HCC) - A PHASE II TRIAL (NEOTOMA)
• ATEZOLIZUMAB AND BEVACIZUMAB PRE-LIVER TRANSPLANTATION FOR PATIENTS WITH HEPATOCELLULAR CARCINOMA BEYOND MILAN CRITERIA: A FEASIBILITY STUDY
• A STUDY TO EVALUATE THE EFFICACY OF PROPRANOLOL IN BOOSTING IMMUNOTHERAPY IN HEPATOCELLULAR CARCINOMA, CHOLANGIOCARCINOMA AND PANCREATIC ADENOCARCINOMA (BLOCKED)
• A PHASE III, RANDOMIZED, OPEN-LABEL, SPONSOR-BLINDED, MULTICENTER STUDY OF DURVALUMAB IN COMBINATION WITH TREMELIMUMAB ± LENVATINIB GIVEN CONCURRENTLY WITH TRANSARTERIAL CHEMOEMBOLIZATION (TACE) COMPARED TO TACE ALONE IN PATIENTS WITH LOCOREGIONAL HEPATOCELLULAR CARCINOMA (EMERALD-3)
• A RANDOMIZED, MULTI-CENTER, DOUBLE-BLINDED, PLACEBO-CONTROLLED PHASE 3 STUDY OF NIVOLUMAB AND IPILIMUMAB, NIVOLUMAB MONOTHERAPY, OR PLACEBO IN COMBINATION WITH TRANS-ARTERIAL CHEMOEMBOLIZATION (TACE) IN PATIENTS WITH INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA (HCC)

View on source registry